Stock Report

Download full stock data and analysis for free Last Updated: 17-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Pieris Pharmaceuticals Inc. (PIRS)

Stock Card factsheet share-fund-plan-icon

$13.26

up-down-arrow $-2.87 (-17.79%)

As on 13-Dec-2024 16:03EDT

Market cap

info icon

$21 Mln

Revenue (TTM)

info icon

$1 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

1.1

Div. Yield

info icon

0 %

Pieris Pharmaceuticals (PIRS) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.8 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -1.5

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    1,320,240

10 Years Aggregate

CFO

$-203.25 Mln

EBITDA

$-243.17 Mln

Net Profit

$-251.26 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Pieris Pharmaceuticals (PIRS)
7,185.7 -17.7 -22.1 8,345.9 61.1 30.8 --
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 13-Dec-2024  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2023
2022
2021
2020
2019
2018
2017
Pieris Pharmaceuticals (PIRS)
-82.5 -72.5 51.2 -30.9 36.1 -64.6 437.3
S&P Small-Cap 600
13.9 -17.4 25.3 9.6 20.9 -9.7 11.7
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Pieris Pharmaceuticals (PIRS)
13.3 21.1 1.4 -16.0 -1,156.1 -83.5 -- 1.1
Longboard Pharmaceuticals (LBPH)
60.0 2,342.0 0.0 -76.3 -1,093,125.0 -25.9 -- 8.5
Lumos Pharma (LUMO)
4.3 37.5 2.2 -34.9 -1,302.3 -312.4 -- 7.6

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO...  bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.  Read more

  • CEO, President & Director

    Mr. Stephen S. Yoder J.D.

  • CEO, President & Director

    Mr. Stephen S. Yoder J.D.

  • Headquarters

    Boston, MA

  • Website

    https://www.pieris.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Pieris Pharmaceuticals (PIRS)

The share price of Pieris Pharmaceuticals Inc (PIRS) is $13.26 (NASDAQ) as of 13-Dec-2024 16:03 EDT. Pieris Pharmaceuticals Inc (PIRS) has given a return of 61.12% in the last 3 years.

Since, TTM earnings of Pieris Pharmaceuticals Inc (PIRS) is negative, P/E ratio is not available.
The P/B ratio of Pieris Pharmaceuticals Inc (PIRS) is 1.10 times as on 13-Dec-2024, a 76 discount to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
--
--
2022
--
--
2021
--
--
2020
--
--
2019
--
--

The 52-week high and low of Pieris Pharmaceuticals Inc (PIRS) are Rs -- and Rs -- as of 17-May-2026.

Pieris Pharmaceuticals Inc (PIRS) has a market capitalisation of $ 21 Mln as on 13-Dec-2024. As per SEBI classification, it is a Small Cap company.

Before investing in Pieris Pharmaceuticals Inc (PIRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.